A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients

Trial Profile

A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 23 Feb 2016 Results published in the Pediatric Infectious Disease Journal
    • 19 Oct 2012 Results were presented at IDWeek in October 2012.
    • 27 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top